About Prismic Pharmaceuticals
Prismic Pharmaceuticals is a Healthcare company based in Worcester (United States) founded in 2011, and was acquired by FSD Pharma in April 2019. Medical drugs for the treatment of inflammation and oxidative stress. Prismic Pharmaceuticals has raised $1.2 million across 1 funding round from investors including FSD Pharma. Prismic Pharmaceuticals offers products and services including Motor Reviews, Buying-Selling Platform, and Motor Information Service. Its focus areas include Diversified Pharmaceuticals.
Company details
Prismic Pharmaceuticals is a development-stage specialty pharmaceutical company, which focuses on the research and development of patent protected products to address inflammation and oxidative stress associated with renal and mental health disorders. Currently has two pharmaceutically active ingredients, ultra-micronized palmitoylethanolamide, and ultra-pure EPA-based Omega-3, in development to address disorders associated with kidney disease, mental health, and chronic pain. Plan to develop proprietary products in two distinct FDA categories, prescription Medical Foods and Prescription Drugs. Medical food pipeline includes Neurepa, Nefrogesic, Nefrosil and Neurepa Le. Prescription Drugs pipeline includes ultra-micronized palmitoylethanolamide (UM PEA) Morphine, UM PEA Pregabalin, UM PEA Hydrocodone, UM PEA Oxycodone, UM PEA and UM PEA Silymarin.
- Headquarters Worcester, United States
- Stage Acquired
- SectorsHealthcare
- Website prismicpharma.com
- Social LinkedIn
- Acquired by FSD Pharma (Apr 2019)
- Total Equity Funding$1.2M (USD)
in 1 rounds
- Latest Funding Round$1.2M (USD), Seed
Feb 2013
- Investors
- Acquired byFSD Pharma
(Apr 2019)
Products & Services of Prismic Pharmaceuticals
Prismic Pharmaceuticals offers a comprehensive portfolio of products and services, including Motor Reviews, Buying-Selling Platform, and Motor Information Service.
Provides detailed reviews and information on popular motor models.
Facilitates online buying and selling of motor-related items.
Offers data on specific motors like Motor 1 and Motor 2.
Funding Insights of Prismic Pharmaceuticals
Prismic Pharmaceuticals has successfully raised a total of $1.2M through 1 strategic funding round. The most recent funding activity was a Seed round of $1.2 million completed in February 2013. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $1.2M
- Total Rounds 1
- Last Round Seed — $1.2M
- First Round $1.2M
(Feb 2013)
All 1 funding rounds of Prismic Pharmaceuticals with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Feb 2013 | $1.2M | Seed | – | – | – |
1 investors in total: 1 institutional.
Investors in Prismic Pharmaceuticals
Prismic Pharmaceuticals has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include FSD Pharma.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Cannabis company engaged in cultivation, processing, and manufacturing related activities | 2018 | fsdpharma.com | Cobourg, Canada |
Investor details for Prismic Pharmaceuticals
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of Prismic Pharmaceuticals
3 dated milestones of Prismic Pharmaceuticals across 8 years, from founding to its latest funding, stage changes and deals.
- Founded Prismic Pharmaceuticals is founded.
- Funding First funding round of $1.2M.
- Exit Acquired by FSD Pharma.
Top companies in Pharmaceuticals & Distribution
3 companies that operate in the same segment as Prismic Pharmaceuticals (Pharmaceuticals & Distribution) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Therapeutics for neurology, oncology, rare, and endocrinology diseases are developed. | 2014 | New York, New York, United States | USD 1.3 B | USD 8.26 M | 750 | |
Developer of pharmaceutical products for treating multiple diseases | 1980 | Thousand Oaks, California, United States | USD 33.23 B | 28,000 | ||
Biopharmaceutical research and drug development are conducted globally by AbbVie. | 2012 | Chicago, Illinois, United States | USD 61.16 B | 55,000 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Prismic Pharmaceuticals
Complete news archive for Prismic Pharmaceuticals
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Prismic Pharmaceuticals
Prismic Pharmaceuticals was founded in 2011 and raised its 1st funding round 2 years after it was founded.
Prismic Pharmaceuticals is headquartered in Worcester, United States. It is registered at Worcester, Massachusetts, United States.
Prismic Pharmaceuticals is a funded company, having raised a total of $1.2M across 1 funding round to date. The company's 1st funding round was a Seed of $1.2M, raised on Feb 2013.
Prismic Pharmaceuticals is a development-stage specialty pharmaceutical company, which focuses on the research and development of patent protected products to address inflammation and oxidative stress associated with renal and mental health disorders. Currently has two pharmaceutically active ingredients, ultra-micronized palmitoylethanolamide, and ultra-pure EPA-based Omega-3, in development to address disorders associated with kidney disease, mental health, and chronic pain. Plan to develop proprietary products in two distinct FDA categories, prescription Medical Foods and Prescription Drugs. Medical food pipeline includes Neurepa, Nefrogesic, Nefrosil and Neurepa Le. Prescription Drugs pipeline includes ultra-micronized palmitoylethanolamide (UM PEA) Morphine, UM PEA Pregabalin, UM PEA Hydrocodone, UM PEA Oxycodone, UM PEA and UM PEA Silymarin.
Prismic Pharmaceuticals offers Motor Reviews, Buying-Selling Platform, and Motor Information Service.
Prismic Pharmaceuticals has 1 investor. Key investors include FSD Pharma.
Yes. Prismic Pharmaceuticals was acquired by FSD Pharma in April 2019.